Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Jialal, I.; Singh, G. Management of diabetic dyslipidemia: An update. World J. Diabetes 2019, 10, 280–290. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Chait, A.; Eckel, R.H.; Vrablik, M.; Zambon, A. Lipid-lowering in diabetes: An update. Atherosclerosis 2024, 394, 117313. [Google Scholar] [CrossRef] [PubMed]
- Béliard, S.; Mourre, F.; Valéro, R. Hyperlipidaemia in diabetes: Are there particular considerations for next-generation therapies? Diabetologia 2024, 67, 974–984. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Grundy, S.M.; Stone, N.J.; Bailey, A.L.; Beam, C.; Birtcher, K.K.; Blumenthal, R.S.; Braun, L.T.; de Ferranti, S.; Faiella-Tommasino, J.; Forman, D.E.; et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139, e1082–e1143, Erratum in Circulation 2019, 139, e1182–e1186. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020, 41, 111–188, Erratum in Eur. Heart J. 2020, 41, 4255. [Google Scholar] [CrossRef] [PubMed]
- Jialal, I.; Olatunbosun, S. Bempedoic Acid, an Inhibitor of Cholesterol Biosynthesis, Reduces Cardiovascular Events. J. Clin. Med. 2023, 12, 3463. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Nissen, S.E.; Lincoff, A.M.; Brennan, D.; Ray, K.K.; Mason, D.; Kastelein, J.J.P.; Thompson, P.D.; Libby, P.; Cho, L.; Plutzky, J.; et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N. Engl. J. Med. 2023, 388, 1353–1364. [Google Scholar] [CrossRef] [PubMed]
- Ray, K.K.; Nicholls, S.J.; Li, N.; Louie, M.J.; Brennan, D.; Lincoff, A.M.; Nissen, S.E.; CLEAR OUTCOMES Committees and Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: Prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2024, 12, 19–28. [Google Scholar] [CrossRef] [PubMed]
- Reiner, Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat. Rev. Cardiol. 2017, 14, 401–411. [Google Scholar] [CrossRef] [PubMed]
- Giammanco, A.; Spina, R.; Cefalù, A.B.; Averna, M. APOC-III: A Gatekeeper in Controlling Triglyceride Metabolism. Curr. Atheroscler. Rep. 2023, 25, 67–76. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kolovou, G.; Kolovou, V.; Katsiki, N. Volanesorsen: A New Era in the Treatment of Severe Hypertriglyceridemia. J. Clin. Med. 2022, 11, 982. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wolska, A.; Yang, Z.H.; Remaley, A.T. Hypertriglyceridemia: New approaches in management and treatment. Curr. Opin. Lipidol. 2020, 31, 331–339. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Bergmark, B.A.; Marston, N.A.; Prohaska, T.A.; Alexander, V.J.; Zimerman, A.; Moura, F.A.; Sabatine, M.S. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N. Engl. J. Med. 2024, 390, 1770–1780. [Google Scholar] [CrossRef] [PubMed]
- Gaudet, D.; Pall, D.; Watts, G.F.; Nicholls, S.J.; Rosenson, R.S.; Modesto, K.; San Martin, J.; Hellawell, J.; Ballantyne, C.M. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024, 9, 620–630. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kosmas, C.E.; Bousvarou, M.D.; Sourlas, A.; Papakonstantinou, E.J.; Peña Genao, E.; Echavarria Uceta, R.; Guzman, E. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia. Clin. Pharmacol. 2022, 14, 49–59. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Rosenson, R.S.; Gaudet, D.; Hegele, R.A.; Ballantyne, C.M.; Nicholls, S.J.; Lucas, K.J.; San Martin, J.; Zhou, R.; Muhsin, M.; Chang, T.; et al. ARCHES-2 Trial Team. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N. Engl. J. Med. 2024; Epub ahead of print. [Google Scholar] [CrossRef] [PubMed]
- Tomlinson, B.; Wu, Q.; Zhong, Y.; Li, Y. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPLT3 Inhibitors. J. Lipid Atheroscler. 2024, 13, 2–20. [Google Scholar] [CrossRef]
- Kamstrup, P.R. Lipoprotein(a) and Cardiovascular Disease. Clin. Chem. 2021, 67, 154–166. [Google Scholar] [CrossRef] [PubMed]
- Kronenberg, F. Lipoprotein(a): From Causality to Treatment. Curr. Atheroscler. Rep. 2024, 26, 75–82. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Swerdlow, D.I.; Rider, D.A.; Yavari, A.; Wikström Lindholm, M.; Campion, G.V.; Nissen, S.E. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: The emerging potential of RNA interference therapeutics. Cardiovasc. Res. 2022, 118, 1218–1231. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Duarte Lau, F.; Giugliano, R.P. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022, 7, 760–769, Erratum in JAMA Cardiol. 2022, 7, 776. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jialal, I.; Gounden, V. Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk. J. Clin. Med. 2024, 13, 4915. https://doi.org/10.3390/jcm13164915
Jialal I, Gounden V. Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk. Journal of Clinical Medicine. 2024; 13(16):4915. https://doi.org/10.3390/jcm13164915
Chicago/Turabian StyleJialal, Ishwarlal, and Verena Gounden. 2024. "Novel and Promising Therapies for Diabetic Dyslipidemia to Mitigate Residual Cardiovascular Risk" Journal of Clinical Medicine 13, no. 16: 4915. https://doi.org/10.3390/jcm13164915